{
    "clinical_study": {
        "@rank": "33382", 
        "arm_group": {
            "arm_group_label": "cetuximab", 
            "arm_group_type": "Experimental", 
            "description": "Patients will be given intensity-modulated radiotherapy,2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin,and weekly cetuximab during radiation therapy."
        }, 
        "brief_summary": {
            "textblock": "The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation\n      against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity\n      and efficacy of this new regimen."
        }, 
        "brief_title": "Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Nasopharyngeal Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed untreated NPC patients\n\n          -  locoregionally advanced (T3-4 or N2-3 M0)\n\n          -  18-65 years\n\n          -  with MRI examinations\n\n          -  ECOG \u2264 2\n\n          -  With written consent\n\n        Exclusion Criteria:\n\n          -  Without a second cancer\n\n          -  Pregnancy\n\n          -  With other severe diseases (blood,liver ,kidney or heart diseases)\n\n          -  Could not be staged properly\n\n          -  Without written consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712919", 
            "org_study_id": "LA-chemoR-c225", 
            "secondary_id": "JSCC-SACT-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "cetuximab", 
                "description": "Patients will be given intensity-modulated radiotherapy(IMRT)", 
                "intervention_name": "Intensity-modulated radiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "cetuximab", 
                "description": "Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin", 
                "intervention_name": "Concurrent chemotherapy with paclitaxel and nedaplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "cetuximab", 
                "description": "Patients will be given cetuximab weekly during radiation therapy", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Nedaplatin", 
                "Cetuximab", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Locoregionally advanced nasopharyngeal carcinoma", 
            "cetuximab", 
            "chemoradiation"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210009"
                }, 
                "name": "Jiangsu Cancer Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study", 
        "other_outcome": {
            "measure": "local-relapse free survival", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "overall_official": {
            "affiliation": "Jiangsu Cancer Institute & Hospital", 
            "last_name": "Xia He, M.D. Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712919"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jiangsu Cancer Institute & Hospital", 
            "investigator_full_name": "Dr. Xia He", 
            "investigator_title": "Director of the department of radiation oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Progress free survival", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "source": "Jiangsu Cancer Institute & Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Cancer Institute & Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}